Skip to main content
BrainCited

Memory Complaints and Cognitive Decline: Data from the GUIDAGE Study1.

Sophie Dardenne, Julien Delrieu, Sandrine Sourdet, Christelle Cantet, Sandrine Andrieu et al.
RCT Journal of Alzheimer's disease : JAD 2017 17 citazioni
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'pmid\u003D28984580'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Tipo di studio
Randomized Controlled Trial
Dimensione del campione
1307
Popolazione
Elderly with subjective cognitive decline, CDR=0
Durata
260 weeks
Intervento
Memory Complaints and Cognitive Decline: Data from the GUIDAGE Study1. Ginkgo biloba extract EGb 761
Comparatore
placebo
Esito primario
cognitive decline (CDR aggravation)
Direzione dell'effetto
Neutral
Rischio di bias
Low

Abstract

BACKGROUND: Subjective cognitive decline (SCD) may be a very early symptom of Alzheimer's disease (AD) and may be associated with a cognitive decline in a cognitively normal population. The McNair and Kahn Scale was used to assess memory complaints in the GuidAge study. OBJECTIVE: Our objectives were to examine if the McNair and Kahn Scale can predict cognitive decline and to screen which (if any) of the question(s) of this scale would better predict this cognitive decline. METHODS: The GuidAge study was a phase III, multicenter, randomized, double blind, placebo-controlled study. Individuals aged 70 years and older, without cognitive impairment (Clinical Dementia Rate (CDR = 0)) at baseline who had spontaneously reported SCD were included in this study. The 20-item version of the McNair and Kahn Scale was used to assess SCD and a standardized neuropsychological assessment was used to assess the cognitive status. RESULTS: 1,307 patients with SCD and with CDR = 0 at baseline were included. During the 5 years of follow-up, 519 patients showed cognitive decline. Incidence of aggravation score of CDR was 13.40% person years (95% CI [12.24-14.56]). Results showed a significant relationship between the McNair and Kahn Scale score and decline in cognitive performance (HR 1.012; 95% CI [1.002-1.021]; p = 0.0156). Among the 20 items, 5 were statistically significant to predict cognitive decline after adjustment. CONCLUSION: SCD is a promising indicator of memory impairment. Our study found that using the McNair and Kahn scale can predict cognitive decline. A 5-item version of this scale could be used to screen patients in clinical practice and in clinical research.

TL;DR

The study found that using the McNair and Kahn scale can predict cognitive decline and a 5-item version of this scale could be used to screen patients in clinical practice and in clinical research.

Used In Evidence Reviews

Similar Papers